PE20161405A1 - Analogos de cortistatina y sintesis y usos de los mismos - Google Patents
Analogos de cortistatina y sintesis y usos de los mismosInfo
- Publication number
- PE20161405A1 PE20161405A1 PE2016000946A PE2016000946A PE20161405A1 PE 20161405 A1 PE20161405 A1 PE 20161405A1 PE 2016000946 A PE2016000946 A PE 2016000946A PE 2016000946 A PE2016000946 A PE 2016000946A PE 20161405 A1 PE20161405 A1 PE 20161405A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- alkyl
- alkenyl
- compounds
- synthesis
- Prior art date
Links
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical class C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 abstract 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920674P | 2013-12-24 | 2013-12-24 | |
| US201461935240P | 2014-02-03 | 2014-02-03 | |
| US201461993329P | 2014-05-15 | 2014-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161405A1 true PE20161405A1 (es) | 2017-01-18 |
Family
ID=52350382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000946A PE20161405A1 (es) | 2013-12-24 | 2014-12-24 | Analogos de cortistatina y sintesis y usos de los mismos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9994582B2 (OSRAM) |
| EP (2) | EP3087080B1 (OSRAM) |
| JP (2) | JP6494631B2 (OSRAM) |
| KR (1) | KR20160101162A (OSRAM) |
| CN (2) | CN110183461A (OSRAM) |
| AP (1) | AP2016009324A0 (OSRAM) |
| AU (2) | AU2014369834B2 (OSRAM) |
| BR (1) | BR112016014760A2 (OSRAM) |
| CA (1) | CA2934819A1 (OSRAM) |
| CL (1) | CL2016001631A1 (OSRAM) |
| CR (1) | CR20160291A (OSRAM) |
| DO (1) | DOP2016000158A (OSRAM) |
| EA (2) | EA030907B1 (OSRAM) |
| EC (1) | ECSP16062174A (OSRAM) |
| ES (1) | ES2709480T3 (OSRAM) |
| GT (1) | GT201600135A (OSRAM) |
| IL (1) | IL246390A0 (OSRAM) |
| MD (1) | MD20160089A2 (OSRAM) |
| MX (1) | MX361652B (OSRAM) |
| MY (1) | MY180383A (OSRAM) |
| NI (1) | NI201600089A (OSRAM) |
| PE (1) | PE20161405A1 (OSRAM) |
| PH (1) | PH12016501258A1 (OSRAM) |
| RU (1) | RU2016126503A (OSRAM) |
| SA (1) | SA516371410B1 (OSRAM) |
| SG (2) | SG11201605178WA (OSRAM) |
| SV (1) | SV2016005234A (OSRAM) |
| TN (1) | TN2016000240A1 (OSRAM) |
| WO (1) | WO2015100420A1 (OSRAM) |
| ZA (1) | ZA201603894B (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY180383A (en) | 2013-12-24 | 2020-11-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
| KR102408261B1 (ko) | 2014-02-03 | 2022-06-10 | 비타이 파마슈티컬즈, 엘엘씨 | Ror-감마의 디하이드로피롤로피리딘 저해제 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| MX2017014338A (es) * | 2015-05-08 | 2018-04-11 | Harvard College | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| KR20180086221A (ko) | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
| AU2016377678A1 (en) * | 2015-12-23 | 2018-07-12 | President And Fellows Of Harvard College | Cortistatin analogs and uses thereof |
| EP3394038A4 (en) * | 2015-12-23 | 2019-08-21 | President and Fellows of Harvard College | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATINE DERIVATIVES |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| KR20180110134A (ko) * | 2016-02-19 | 2018-10-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 코르티스타틴 유사체 |
| WO2018027082A1 (en) * | 2016-08-03 | 2018-02-08 | The Broad Institute, Inc. | Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity |
| CN110234648B (zh) | 2017-01-30 | 2022-06-14 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| CN107028956A (zh) * | 2017-03-06 | 2017-08-11 | 刘杰 | 一种治疗经期抑郁症的药物组合物 |
| IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| US12410194B2 (en) | 2019-11-26 | 2025-09-09 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of CDK8 and CDK19 |
| TW202330910A (zh) | 2021-09-27 | 2023-08-01 | 國立大學法人京都大學 | Ｔ細胞的製造方法 |
| CA3238860A1 (en) | 2021-11-24 | 2023-06-01 | Norihisa MIKAMI | Pharmaceutical composition for treating or preventing t cell-related disorders |
| TW202330911A (zh) | 2021-11-24 | 2023-08-01 | 日商雷格細胞股份有限公司 | 人類誘導性控制性ｔ細胞及其製作方法 |
| EP4497822A1 (en) | 2022-03-23 | 2025-01-29 | Kyoto University | Method for producing regulatory t cells |
| EP4600352A1 (en) | 2022-09-26 | 2025-08-13 | Kyoto University | T cell production method |
| CN119948155A (zh) | 2022-09-26 | 2025-05-06 | 雷格细胞股份有限公司 | 含有嵌合抗原受体（car）的诱导性调节性t细胞 |
| CN120676951A (zh) | 2023-02-08 | 2025-09-19 | 雷格细胞股份有限公司 | 用于治疗或预防天疱疮的药物组合物 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2886589A (en) | 1957-08-05 | 1959-05-12 | Merck & Co Inc | 8-methyl-5-oxyphenyl hexahydroindan compounds |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5098443A (en) | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5185152A (en) | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| IL105050A0 (en) | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5554187A (en) | 1995-08-18 | 1996-09-10 | Rizzo, Iii; Joseph | Medication dispensing intra-ocular lens system |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US6074872A (en) | 1996-05-15 | 2000-06-13 | The Scripps Research Institute | Cortistatin: nucleic acids that encode these neuropeptides |
| ZA978537B (en) | 1996-09-23 | 1998-05-12 | Focal Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages. |
| AU5902398A (en) | 1996-12-31 | 1998-07-31 | Human Genome Sciences, Inc. | Cortistatin polypeptides |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| CA2372493A1 (en) | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
| CA2669753C (en) | 1999-09-30 | 2012-06-26 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| AU781524B2 (en) | 1999-10-13 | 2005-05-26 | Johns Hopkins University School Of Medicine, The | Regulators of the hedgehog pathway, compositions and uses related thereto |
| CA2388939C (en) | 1999-10-25 | 2009-06-09 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatments for blood cell deficiencies |
| CN1827621A (zh) * | 2000-03-31 | 2006-09-06 | 萨诺化学药物股份公司 | 雪花胺的新衍生物和类似物 |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| ITMI20011445A1 (it) | 2001-07-06 | 2003-01-06 | Europ Geie | Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita |
| US20030236439A1 (en) | 2002-01-30 | 2003-12-25 | Gregory Agoston | Non-steroidal analogs of 2-methoxyestradiol |
| DE60327946D1 (de) | 2002-12-24 | 2009-07-23 | Univ British Columbia | Angiogen-wirkende trisulfat steroide und deren verwendung |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| WO2005030120A2 (en) | 2003-05-28 | 2005-04-07 | Entremed, Inc. | Antiangiogenic agents |
| CA2532802C (en) * | 2003-07-24 | 2013-11-19 | Merck & Co., Inc. | Antibiotic compound isolated from streptomyces sp |
| US20070004689A1 (en) | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
| GB0421106D0 (en) | 2004-09-22 | 2004-10-27 | Sterix Ltd | Compound |
| DK2206719T3 (en) | 2005-03-02 | 2015-01-26 | Univ Maryland | A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN |
| BRPI0706377A2 (pt) | 2006-01-09 | 2011-03-22 | Btg Int Ltd | moduladores de fator -1 induzìvel por hipoxia e usos relacionados |
| WO2007082980A1 (es) | 2006-01-23 | 2007-07-26 | Consejo Superior De Investigaciones Científicas | Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina |
| WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| MX2008014353A (es) * | 2006-05-09 | 2008-11-24 | Merck & Co Inc | Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos. |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008064425A1 (en) | 2006-11-30 | 2008-06-05 | Solbec Pharmaceuticals Limited | Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof |
| KR20090101278A (ko) | 2006-12-22 | 2009-09-24 | 인더스트리얼 리서치 리미티드 | 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체 |
| CA2679845A1 (en) | 2007-03-07 | 2008-09-12 | Infinity Discovery, Inc. | Cyclopamine lactam analogs and methods of use thereof |
| US8604004B2 (en) * | 2007-10-04 | 2013-12-10 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| CA2723689C (en) * | 2008-05-05 | 2016-07-05 | Ryan A. Shenvi | Synthesis of (+) cortistatin a and related compounds |
| EP2334686B1 (en) * | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
| WO2010123545A2 (en) | 2009-04-22 | 2010-10-28 | President And Fellows Of Harvard College | Angiogenesis inhibitors |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| CN103003281A (zh) | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
| WO2012036287A1 (ja) | 2010-09-17 | 2012-03-22 | 国立大学法人大阪大学 | 新規コルチスタチンａ類似体およびその用途 |
| EP2663574A4 (en) | 2011-01-10 | 2014-12-17 | Scripps Research Inst | RETRO VIRUS REPLICATION INHIBITORS |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
| WO2013122609A1 (en) | 2012-02-17 | 2013-08-22 | Genentech, Inc. | Methods of using cdk8 antagonists |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| EP2961409A1 (en) | 2013-02-26 | 2016-01-06 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| WO2014199377A1 (en) | 2013-06-10 | 2014-12-18 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression |
| WO2015040089A1 (en) | 2013-09-18 | 2015-03-26 | Bcn Peptides S.A. | Co rti statin analogues for the treatment of inflammatory and/or immune diseases |
| MY180383A (en) | 2013-12-24 | 2020-11-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
-
2014
- 2014-12-24 MY MYPI2016001176A patent/MY180383A/en unknown
- 2014-12-24 CN CN201910351186.8A patent/CN110183461A/zh active Pending
- 2014-12-24 EA EA201691167A patent/EA030907B1/ru not_active IP Right Cessation
- 2014-12-24 AP AP2016009324A patent/AP2016009324A0/en unknown
- 2014-12-24 CN CN201480076267.7A patent/CN106103452B/zh not_active Expired - Fee Related
- 2014-12-24 WO PCT/US2014/072365 patent/WO2015100420A1/en not_active Ceased
- 2014-12-24 SG SG11201605178WA patent/SG11201605178WA/en unknown
- 2014-12-24 AU AU2014369834A patent/AU2014369834B2/en not_active Ceased
- 2014-12-24 BR BR112016014760A patent/BR112016014760A2/pt not_active Application Discontinuation
- 2014-12-24 SG SG10201808151RA patent/SG10201808151RA/en unknown
- 2014-12-24 EP EP14827687.6A patent/EP3087080B1/en active Active
- 2014-12-24 JP JP2016542733A patent/JP6494631B2/ja not_active Expired - Fee Related
- 2014-12-24 MX MX2016008436A patent/MX361652B/es active IP Right Grant
- 2014-12-24 PE PE2016000946A patent/PE20161405A1/es unknown
- 2014-12-24 EA EA201891279A patent/EA201891279A1/ru unknown
- 2014-12-24 EP EP18205981.6A patent/EP3505521A1/en not_active Withdrawn
- 2014-12-24 TN TN2016000240A patent/TN2016000240A1/en unknown
- 2014-12-24 MD MDA20160089A patent/MD20160089A2/ro not_active Application Discontinuation
- 2014-12-24 CA CA2934819A patent/CA2934819A1/en not_active Abandoned
- 2014-12-24 ES ES14827687T patent/ES2709480T3/es active Active
- 2014-12-24 RU RU2016126503A patent/RU2016126503A/ru not_active Application Discontinuation
- 2014-12-24 KR KR1020167019783A patent/KR20160101162A/ko not_active Withdrawn
- 2014-12-24 CR CR20160291A patent/CR20160291A/es unknown
-
2016
- 2016-06-08 ZA ZA2016/03894A patent/ZA201603894B/en unknown
- 2016-06-22 IL IL246390A patent/IL246390A0/en unknown
- 2016-06-23 NI NI201600089A patent/NI201600089A/es unknown
- 2016-06-23 CL CL2016001631A patent/CL2016001631A1/es unknown
- 2016-06-24 SV SV2016005234A patent/SV2016005234A/es unknown
- 2016-06-24 DO DO2016000158A patent/DOP2016000158A/es unknown
- 2016-06-24 GT GT201600135A patent/GT201600135A/es unknown
- 2016-06-24 SA SA516371410A patent/SA516371410B1/ar unknown
- 2016-06-24 US US15/192,629 patent/US9994582B2/en active Active
- 2016-06-24 PH PH12016501258A patent/PH12016501258A1/en unknown
- 2016-07-20 EC ECIEPI201662174A patent/ECSP16062174A/es unknown
-
2018
- 2018-05-16 US US15/981,575 patent/US10273241B2/en not_active Expired - Fee Related
-
2019
- 2019-03-04 JP JP2019038398A patent/JP2019108367A/ja not_active Withdrawn
- 2019-03-05 US US16/293,410 patent/US10508121B2/en not_active Expired - Fee Related
- 2019-03-19 AU AU2019201888A patent/AU2019201888A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CL2011002825A1 (es) | Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| PE20080524A1 (es) | DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| CO6640226A2 (es) | 5-fluoro-1h-pirazolipiridinas sustituidas y su uso | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| PE20160691A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CL2018000533A1 (es) | Compuestos antibacterianos 1,2–dihidro–3h–pirrolo[1,2–c]imidazol–3–ona sustituidos |